[Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells]. / Präklinische Studien zum Einfluss des Tyrosinkinaseinhibitors AEE788 auf die Malignität des Nierenzellkarzinoms.
Urologe A
; 47(9): 1175-81, 2008 Sep.
Article
em De
| MEDLINE
| ID: mdl-18688594
ABSTRACT
BACKGROUND:
Conventional therapeutic approaches to treat advanced renal cell carcinoma (RCC) are of limited benefit. Receptor tyrosine kinase inhibitors (RTKI) may open up novel treatment options. In the present study, the effects of the RTKI AEE788 on the growth and adhesion capacity of RCC cell lines were evaluated in vitro. MATERIALS ANDMETHODS:
RCC cells were treated with AEE788, and alterations of tumor growth and tumor cell interaction with vascular endothelium or extracellular matrix proteins were analyzed. Furthermore, the addition of interferon alpha (IFNalpha) was investigated to see whether it may enhance the anti-tumoral potential of AEE788.RESULTS:
AEE788 significantly blocked RCC cell growth and adhesion. Analysis of alpha- and beta-integrins revealed distinct alterations of the receptor expression profile and downregulation of integrin-dependent signaling. Growth-blocking effects were further enhanced when the AEE788-IFNalpha combination protocol was applied. In addition, downregulation of integrin-dependent signaling was more intense in the presence of a combination of AEE788 and IFNalpha than with AEE788 monotherapy.CONCLUSIONS:
AEE788 exerts significant anti-tumoral properties, particularly when combined with IFNalpha. AEE788 may therefore be an encouraging compound to treat advanced RCC.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Purinas
/
Carcinoma de Células Renais
/
Adesão Celular
/
Divisão Celular
/
Receptores de Fatores de Crescimento do Endotélio Vascular
/
Receptores ErbB
/
Neoplasias Renais
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
De
Revista:
Urologe A
Ano de publicação:
2008
Tipo de documento:
Article